ReviewF1000Research2019
Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria.
Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Analysis of microorganisms isolated from tracheal aspirate cultures and their antibiotic susceptibility profiles: a retrospective study from 2018 to 2022.Frontiers in medicine · 2026Article
- Spermine-Functionalized Multiepitope Signaling Peptide Nanovaccine to Stimulate the Systemic Immunity against Pneumonia.ACS pharmacology & translational science · 2025Article
- Molecular Detection of Antibiotic Resistance Genes Using Respiratory Sample from Pneumonia Patients.Antibiotics (Basel, Switzerland) · 2025Article
- Determination of Antibiotic Resistance Genes in the Interior Bay of Puno-Peru, Lake Titicaca.Scientifica · 2025Article
- Drug-Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians.Pharmaceutics · 2024Review
- Formulation and Evaluation of pH-Modulated Amorphous Solid Dispersion-Based Orodispersible Tablets of Cefdinir.Pharmaceutics · 2024Article
- Review
- Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study.Annals of intensive care · 2023Article
- Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study.Journal of intensive care · 2023Article
- Molecular Epidemiology of Clinical Carbapenem-ResistantTropical medicine and infectious disease · 2022Article
- Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns.Pneumonia (Nathan Qld.) · 2022Review
- Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Article
- Comparison of colistin-induced nephrotoxicity between two different formulations of colistin in critically ill patients: a retrospective cohort study.Antimicrobial resistance and infection control · 2021Article
- In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).BMC infectious diseases · 2021Article
- Article
- Salvadora persica mediated synthesis of silver nanoparticles and their antimicrobial efficacy.Scientific reports · 2021Article
- High clinical impact of rapid susceptibility testing on CHROMID ESBLAnnals of translational medicine · 2020Article
- The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections.Open forum infectious diseases · 2020Article
- A proposal for a comprehensive approach to infections across the surgical pathway.World journal of emergency surgery : WJES · 2020Review
- Distribution of Antibiotic Resistance Genes in Three Different Natural Water Bodies-A Lake, River and Sea.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Pneumonia is one of the most common infections worldwide. Morbidity, mortality, and healthcare costs increase substantially when pneumonia is caused by multidrug-resistant Gram-negative bacteria (MDR-GNB). The ongoing spread of antimicrobial resistance has made treating MDR-GNB pneumonia increasingly difficult. Fortunately, there have been some recent additions to our antibiotic armamentarium in the US and Europe for MDR-GNB, along with several agents that are in advanced stages of development. In this article, we review the risk factors for and current management of MDR-GNB pneumonia as well as novel agents with activity against these important and challenging pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.